SynthesisEuropean journal of pediatrics2026
Innovations in transcatheter interventions for hypoplastic left heart syndrome and borderline left heart structures from fetal to neonatal life: current evidence and systematic review of recent advances (2016-2025).
Synthesis in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alongside advances in surgical and medical care, catheter-based interventions have reshaped the care of fetuses and neonates with hypoplastic left heart syndrome (HLHS) or borderline left heart structures over the last decades. These interventions include fetal aortic valvuloplasty (FAV), fetal and neonatal atrial septal interventions, the hybrid Stage-1 procedure (HS1P), and the emerging total transcatheter Stage-1 procedure (TTS1P). We summarize the current evidence on catheter-based interventions for HLHS and borderline left heart structures from fetal to neonatal life and systematically review recent advances (2016-2025). Among 361 studies identified (+ 12 manually), 68 were included (17: FAV, 4: fetal/neonatal atrial septal interventions, 39: HS1P, 8: TTS1P). FAV outcomes have continued to improve over time, confirming its potential to alter the progression to HLHS in selected patients. In patients with HLHS and an intact or severely restrictive atrial septum, fetal and neonatal atrial septal interventions can mitigate severe perinatal respiratory failure; however, outcomes in this population remain significantly burdened by underlying lung disease. In the neonatal period, both HS1P and TTS1P offer less invasive alternatives to the surgical Stage-1 procedure, spanning both univentricular and biventricular recruitment pathways. HS1P offers a cardiopulmonary bypass-sparing strategy with favorable outcomes in experienced centers. TTS1P further reduces invasiveness by eliminating both sternotomy and cardiopulmonary bypass and has demonstrated promising early results. As techniques, devices, and patient selection continue to evolve, further research will be critical to establish the most appropriate application of each approach and to align prenatal and postnatal management pathways to optimize outcomes.
Indexed as
Identifiers
42629491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.